Tarlatamab improved PFS and OS over chemotherapy as second-line treatment in patients with SCLC in the phase 3 DeLLphi-304 trial.

The secrets of idiopathic pulmonary fibrosis (IPF) are written in its very name. Idiopathic refers to a disease of unknown ...

Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

Amgen Inc. (NASDAQ:AMGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 2, Amgen announced new interim ...

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

MISSISSAUGA, ON, April 10, 2025 /CNW/ - Health Canada has granted a Notice of Compliance (NOC) for IMFINZI® (durvalumab), as monotherapy, for the treatment of adult patients with limited-stage ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...